Skip to Main Content
Read Upsher-Smith’s Statement on Pending Minnesota Generic Drug Price-Gouging Legislation


Upsher-Smith Wins Silver Stevie at 2018 American Business Awards

RECOGNIZED FOR ITS INTERNAL COMMUNICATIONS PLAN FOR SAWAI Stevie® Award Presentation to Upsher-Smith Left to right: Daina Basile (Kovak-Likly Communications), Elizabeth Likly (Kovak-LiklyCommunications), Jennifer Colvin (Upsher-Smith), Carol Weeklund (Upsher-Smith) PHARMACEUTICALS’ACQUISITION OF UPSHER-SMITH LABORATORIES Maple Grove, MN – June ...
Read More

MHLW Approves New Indication for OSELTAMIVIR Capsules 75mg [SAWAI] / Dry Syrup 3% [SAWAI]

Osaka, Japan –June 6, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OSELTAMIVIR  Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI]*. This approval expands the indication of OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI] to include the ...
Read More

MHLW Approves New Indication for OLANZAPINE Formulation and New Administration for MEROPENEM Formulation

Osaka, Japan –April 4, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of two partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OLANZAPINE Tablets 2.5mg “SAWAI”, 5mg “SAWAI”, 10mg “SAWAI” and Fine Granules 1% “SAWAI” ...
Read More

Join Our Team!

We’re hiring

Search Our Jobs